Weight-Loss drug semaglutide tested as heart failure treatment
NCT ID NCT05371496
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This study looks at whether aggressive weight loss using semaglutide can improve symptoms in people with a specific type of heart failure linked to obesity. About 81 participants with a BMI of 30 or higher and heart failure with preserved ejection fraction will receive either semaglutide or a placebo. The main goal is to measure changes in heart pressure during exercise.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOMYOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Timing your meals or halving your rice: a new trial tests simple diet hacks for weight loss and blood sugar control
- Does injection location matter for a new Weight-Loss drug? a trial investigates
- Can a new drug boost Semaglutide's power against diabetes and obesity?
- Can a Normal-Weight baseline improve heart risk assessment in type 1 diabetes?
- A daily pill for obesity? zenagamtide faces its biggest test yet.
- Dance and walking may boost heart health in obesity — a trial puts it to the test